^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

CD44 (CD44 Molecule)

i
Other names: CD44, CD44 Molecule (Indian Blood Group), HUTCH-I, HCELL, CSPG8, MC56, Pgp1, MDU2, MDU3, MIC4, IN, Hematopoietic Cell E- And L-Selectin Ligand, GP90 Lymphocyte Homing/Adhesion Receptor, Chondroitin Sulfate Proteoglycan 8, Extracellular Matrix Receptor III, Homing Cell Adhesion Molecule, Heparan Sulfate Proteoglycan, Phagocytic Glycoprotein 1, Phagocyte Glycoprotein 1, Hyaluronate Receptor, In(Lu) Related-P80, Hermes Antigen, CD44 Antigen, Hermes-1, ECMR-III, HUTCH-1, ECM-III, Epican, PGP-1, CD44R, CDw44, H-CAM, LHR, CD44 Antigen (Homing Function And Indian Blood Group System), Homing Function And Indian Blood Group System, Extracellular Matrix Receptor-III, Cell Surface Glycoprotein CD44, Indian Blood Group Antigen, Phagocytic Glycoprotein I, Soluble CD44, CDW44, PGP-I
5d
GPX2+ tumor cells recruit LGALS1+ B cells via CCL26-CCR3 axis to promote immunosuppression and tumor progression in hepatocellular carcinoma. (PubMed, Front Immunol)
In vivo, GPX2 overexpression accelerates tumorigenesis, whereas targeting CCR3 with ALK4290 sensitizes tumors to anti-PD-1 checkpoint blockade. These findings delineate a dual mechanism whereby GPX2 couples oxidative stress regulation to immune modulation, positioning the GPX2-B cell axis as a promising therapeutic target for HBV-driven liver cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD44 (CD44 Molecule) • LGALS1 (Galectin 1) • GPX2 (Glutathione peroxidase 2 (gastrointestinal)) • CCR3 (C-C Motif Chemokine Receptor 3)
10d
Pre-existing cell states predict resistance to multiple treatments. (PubMed, Cell Genom)
Additionally, we found that differences in pre-treatment gene expression states can lead cells within the same treatment condition to follow divergent paths toward their ultimate resistance fate. This work provides a framework for extracting targetable gene expression states from complex resistance dynamics to eliminate multi-treatment resistance.
Journal
|
CD44 (CD44 Molecule)
10d
Zinc-coordination-driven mitochondrial nanodisruptors to ablate cancer stemness for potentiating immunotherapy in colorectal malignancies. (PubMed, J Nanobiotechnology)
In translational models, HA/ZGA achieves potent tumor regression, suppresses metastasis, and establishes immunological memory against rechallenge. Our work redefines ZIF-8 as a therapeutic chameleon that dismantles mitochondrial energetics, ablates stemness, and reignites antitumor immunity, exemplifying nanomaterial repurposing to bridge metabolic intervention with immune potentiation.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD44 (CD44 Molecule)
|
PD-L1 expression
14d
Albendazole loaded chitosan nanoparticle conjugated with hyaluronic acid for the treatment of psoriasis. (PubMed, Drug Dev Ind Pharm)
In-vivo studies conducted on Balb/c mice showed reduced Psoriasis Area Severity Index, Spleen weight as well as reduced keratinocyte proliferation in histopathological studies. In conclusion, developed novel formulation of Albendazole reduced keratinocyte proliferation making it a possible effective strategy in the management of psoriasis.
Journal
|
CD44 (CD44 Molecule)
14d
Deciphering the Role of Cancer Stem Cells in Breast Cancer Brain Colonization Using a Novel Patient-Derived Model. (PubMed, Adv Healthc Mater)
High-throughput drug screening indicates broad therapeutic resistance within the CSC compartment. Through the comprehensive characterization of BCBM-derived CSCs, this study establishes a clinically relevant model that identifies CSCs and the MIC subpopulation as key drivers of brain metastatic progression and as promising targets for the development of effective therapeutic strategies.
Journal
|
CD44 (CD44 Molecule) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)
14d
Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC. (PubMed, Cell Biochem Funct)
In conclusion, PrP knockdown may sensitize resistant SCLC cells to doxorubicin and promote autophagy. These findings support PrP silencing as a promising strategy to reverse chemoresistance in SCLC.
Journal
|
CD44 (CD44 Molecule) • BAX (BCL2-associated X protein) • BECN1 (Beclin 1) • PRNP (Prion Protein)
|
doxorubicin hydrochloride
15d
Blue light photobiomodulation attenuates aggressiveness and stemness features in oral squamous carcinoma cells. (PubMed, Arch Oral Biol)
Blue light irradiation reduced viability and migration in both OSCC cell lines and induced apoptosis only in non-metastatic SCC9 cells. Blue light exerted anti-tumor effects without promoting cancer stem cells properties, while decreasing their ability to self-renew.
Journal
|
CD44 (CD44 Molecule) • POU5F1 (POU Class 5 Homeobox 1) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • NANOG (Nanog Homeobox) • ANXA5 (Annexin A5)
|
POU5F1 expression
15d
Hyaluronic Acid Decoration Facilitates CD44-Mediated Targeting and Alters Protein Corona Formation of Extracellular Vesicles. (PubMed, J Extracell Vesicles)
HA-decoration was found to cause a formation of thicker corona and enrichment of plasma-derived protein corona components. These findings highlight the role of HA in enhancing CD44-mediated EV targeting and modulating the composition of protein corona.
Journal
|
CD44 (CD44 Molecule)
16d
Molecular switching from morule to squamous metaplasia via p40 and the EBP50/S100A4/myosin 9 axis in endometrial carcinoma. (PubMed, Am J Pathol)
Collectively, p40 is an initial signal for squamous metaplasia development from morular and Sur Ca cells, by modulating CSC properties. This leads to terminal squamous differentiation through the MYH9 monomer-polymer equilibrium, regulated by EBP50 and S100A4 under hypoxic conditions.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD44 (CD44 Molecule) • EZR (Ezrin) • MYH9 (Myosin Heavy Chain 9) • S100A4 (S100 calcium binding protein A4) • RDX (Radixin)
17d
Immunocytochemical Analysis of Stem Cell Markers in Pancreatic Adenocarcinoma. (PubMed, Cytopathology)
OCT4 expression is a specific biomarker for PDAC. Its increased expression signified PDAC progression and CD24 activation in a subset of PDAC. KRAS mutants have lower OCT4 expression, suggesting an alternative mechanism for cancer progression than that in OCT4 positive PDAC.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CD44 (CD44 Molecule) • CD24 (CD24 Molecule) • POU5F1 (POU Class 5 Homeobox 1)
|
KRAS mutation • POU5F1 expression
22d
Cuproptosis-inducing photothermal nanotherapy coupled with ECM destabilization drives potent tumor regression and immune reawakening. (PubMed, Mater Today Bio)
The system consisted of hollow copper sulfide nanoparticles loaded with 4-methylumbelliferone, modified with polymetformin, and surface-coated with hyaluronic acid to ensure targeted delivery via CD44 receptors...Furthermore, immunostaining confirmed that apoptosis, macrophage repolarization, and immune activation were increased. This research presents a synergistic nanoplatform that integrates matrix remodeling, photothermal therapy (PTT), and immune reprogramming, offering a promising strategy for treating metastatic and immune-evasive breast tumors.
Journal
|
CD44 (CD44 Molecule)
|
metformin
25d
Increased CD44 Expression in Endothelial Cells Induced by Advanced Glycation End Products Leads to Insufficient Maturation of Angiogenesis. (PubMed, J Cell Mol Med)
When this interaction was blocked by LF3, AGEs-induced CD44 upregulation was reduced, and pathological angiogenesis and BM abnormalities were partially restored. These findings suggest that AGEs upregulate endothelial CD44 expression via β-catenin/TCF4 signalling pathway, which in turn promotes MMP9-mediated excessive degradation of BM components, leading to structural disorganisation and impaired vascular maturation in pathological angiogenesis.
Journal
|
CD44 (CD44 Molecule) • MMP9 (Matrix metallopeptidase 9) • TCF4 (Transcription Factor 4)